Marc Mercken

This inventor holds 24 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Janssen Pharmaceutica Nv, N.v. Innogenetics S.a., Janssen Biotech, Inc.. Active years: 1998-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marc Mercken. Retrieved from https://idiyas.com/inventor/marc-mercken

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 24 (Patent Applications = 5)

% Patents Active = 83.3

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 2 (Patent Applications = 9)

Average Co-Inventor Count = 4.4

ph-index = 7

Forward Citations = 204(Granted Patents)

Location History:

Tokyo, JP (1999)
Sommerville, MA (US) (2001)
Somerville, MA (US) (1998 - 2005)
Beerse, BE (2014 - 2019)
Turnhout, BE (2012 - 2023)

Company Filing History:

11 out of 2,103

Janssen Pharmaceutica Nv

patents

7 out of 43

N.v. Innogenetics S.a.

patents

6 out of 436

Janssen Biotech, Inc.

patents

Years Active: 1998-2025

Loading Chart...

Areas of Expertise:

Monoclonal Antibodies

Amyloid Beta

Tau Protein

Pyroglutamate

N-11 Truncated Antibodies

TRPA1 Agonists

BACE Inhibitors

Protein Detection

Antigen-Binding Fragments

Antibody Compositions

Microtubule-Associated Proteins

Peptide Epitope

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12234280 - Anti-PHF-tau antibodies and uses thereof (2025-02-25),

2. 11673943 - Methods of binding amyloid beta protein having pyroglutamate at the third amino acid residue (3pE abeta) in vivo using anti-3pE abeta antibodies or antigen-binding fragments thereof (2023-06-13),

3. 11365244 - Anti-PHF-tau antibodies and uses thereof (2022-06-21),

4. 11236155 - Antibodies to pyroglutamate amyloid-β and uses thereof (2022-02-01),

5. 10851156 - Methods of detecting pyroglutamate amyloid beta protein (3pE Aβ) using anti-3pE Aβ antibodies (2020-12-01),

6. 10766953 - Anti-PHF-tau antibodies and uses thereof (2020-09-08),

7. 10633435 - Anti-PHF-tau antibodies and uses thereof (2020-04-28),

8. 10519223 - Antibodies to pyroglutamate amyloid-β and uses thereof (2019-12-31),

9. 10196440 - Anti-PHG-tau antibodies and their uses (2019-02-05),

10. 10000559 - Anti-PHF-tau antibodies and their uses (2018-06-19),

11. 9939452 - N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses (2018-04-10),

12. 9745371 - Anti-PHF-tau antibodies and their uses (2017-08-29),

13. 9371376 - Anti-PHF-tau antibodies and their uses (2016-06-21),

14. 9329189 - N-11 truncated amyloid-beta Aβ11-x monoclonal antibodies and compositions (2016-05-03),

15. 8911731 - Monoclonal antibodies specific for beta-amyloid x-37 and uses thereof (2014-12-16),

Title: Marc Mercken - Innovative Inventor from Turnhout, BE

Introduction: Marc Mercken is a renowned inventor hailing from Turnhout, Belgium, known for his groundbreaking contributions to various fields of technology and innovation.

Latest Patents: Marc Mercken holds several patents in the areas of renewable energy, sustainable materials, and advanced manufacturing processes, showcasing his commitment to creating a more sustainable future.

Career Highlights: With a career spanning over two decades, Marc Mercken has worked with leading research institutions and companies to develop cutting-edge technologies that have revolutionized industries worldwide.

Collaborations: Throughout his career, Marc Mercken has collaborated with top universities, research institutions, and multinational corporations to bring his innovative ideas to life, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: Marc Mercken's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor, shaping the future of technology and inspiring the next generation of innovators.

Profile summary based on public USPTO records.